Should a 71-year-old woman with total cholesterol 244 mg/dL, triglycerides 68 mg/dL, high-density lipoprotein (HDL) 96 mg/dL, calculated low-density lipoprotein (LDL) 134 mg/dL, non‑high-density lipoprotein (non‑HDL) 148 mg/dL, and no prior history of heart disease or stroke be started on a statin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Should This 71-Year-Old Woman Be Started on a Statin?

Yes, initiate moderate-intensity statin therapy in this 71-year-old woman for primary prevention, given her LDL-C of 134 mg/dL and favorable overall lipid profile with excellent HDL-C of 96 mg/dL.

Rationale for Treatment Decision

Age-Specific Considerations for Primary Prevention

For patients over 75 years of age without established cardiovascular disease, the 2018 AHA/ACC guidelines provide a Class IIa recommendation (reasonable to initiate) for moderate- or high-intensity statin therapy after evaluating potential for ASCVD risk reduction, adverse effects, drug-drug interactions, frailty, and patient preferences 1. At age 71, this patient falls just below the threshold where evidence becomes more limited, making her a stronger candidate for treatment.

The guidelines specifically note that for patients aged 40-75 years with LDL-C 70-189 mg/dL (she has 134 mg/dL), statin therapy should be considered based on risk assessment 1. Her age of 71 places her in a category where moderate-intensity statin therapy is reasonable, particularly given her elevated LDL-C.

Lipid Profile Analysis

Her lipid values reveal:

  • LDL-C 134 mg/dL: Above the optimal target of <100 mg/dL for primary prevention 2
  • Non-HDL-C 148 mg/dL: Above the recommended <130 mg/dL threshold 3, 4
  • HDL-C 96 mg/dL: Exceptionally protective (well above the >50 mg/dL goal for women) 3
  • Triglycerides 68 mg/dL: Excellent (<150 mg/dL target) 3

While her high HDL-C is protective, non-HDL-C remains an important marker of residual cardiovascular risk even when LDL-C appears only moderately elevated 5, 6. Research demonstrates that at any LDL-C level, elevated non-HDL-C independently predicts coronary heart disease risk 5.

Treatment Approach

Start with moderate-intensity statin therapy (e.g., atorvastatin 10-20 mg or rosuvastatin 5-10 mg) aiming for:

  • LDL-C reduction of 30-49% (target <100 mg/dL, ideally <70 mg/dL) 1
  • Non-HDL-C <130 mg/dL 3, 4

The moderate-intensity approach is preferred over high-intensity in this age group because:

  1. Lower risk of adverse effects while maintaining efficacy 1
  2. Better tolerability in older adults 7, 8
  3. Adequate LDL-C reduction given her baseline of 134 mg/dL

Critical Discussion Points with Patient

Before initiating therapy, engage in shared decision-making addressing:

  • Potential benefits: 20-22% relative risk reduction for each 1 mmol/L (38.7 mg/dL) LDL-C reduction 9
  • Life expectancy considerations: If reasonable life expectancy (3-5+ years) and no significant frailty, benefits likely outweigh risks 1
  • Adverse effects: Small risk of myalgias, minimal diabetes risk with moderate-intensity statins, no clear cognitive impairment 10
  • Monitoring plan: Lipid panel at 4-6 weeks, then every 3-6 months initially 11

Common Pitfalls to Avoid

  1. Don't dismiss treatment based solely on age: The evidence supports statin use in carefully selected patients in their early 70s for primary prevention 1, 10

  2. Don't focus only on LDL-C: Her non-HDL-C of 148 mg/dL indicates residual atherogenic particle burden that warrants treatment 5, 6

  3. Don't use high-intensity statins initially: In this age group without established ASCVD, moderate-intensity is more appropriate and better tolerated 1

  4. Don't neglect lifestyle modification: Emphasize Mediterranean-style diet, regular physical activity (150 minutes/week moderate intensity), and weight management as foundational therapy 9

Monitoring Strategy

After initiating moderate-intensity statin:

  • Recheck lipids in 4-6 weeks to assess response 11
  • Target LDL-C <100 mg/dL (or 30-49% reduction from baseline) 1
  • If target not achieved: Consider increasing to high-intensity statin or adding ezetimibe, though this is less commonly needed in primary prevention 1
  • Monitor for adverse effects: Assess muscle symptoms, liver enzymes at baseline and as clinically indicated 8

The combination of her age (71), elevated LDL-C and non-HDL-C, and absence of contraindications makes moderate-intensity statin therapy a reasonable and evidence-based recommendation for primary cardiovascular disease prevention 1, 9.

References

Guideline

a comparative analysis of current lipid treatment guidelines: nothing stands still.

Journal of the American College of Cardiology, 2018

Related Questions

Given a total cholesterol of 280 mg/dL, LDL cholesterol of 188 mg/dL, HDL cholesterol of 74 mg/dL, and triglycerides of 87 mg/dL, what is the appropriate management?
In a 76-year-old woman taking simvastatin (Zocor) 20 mg, how should mildly elevated triglycerides be managed?
What is the recommended management for an otherwise healthy 11‑year‑old male with a non‑fasting triglyceride level of 139 mg/dL and a normal remaining lipid panel?
How should a 33-year-old woman with an LDL cholesterol of 191 mg/dL who exercises regularly and follows a low‑fat diet be managed?
What is the appropriate management for a 34‑year‑old woman with total cholesterol 221 mg/dL, LDL‑C 121 mg/dL, and HDL‑C 83 mg/dL?
Does duloxetine affect hepatic enzyme activity?
What is the appropriate renal dosing of cephalexin (Keflex) 500 mg for a patient on hemodialysis with a creatinine clearance of 16 mL/min, who receives dialysis on Tuesday, Thursday, and Saturday?
How should I evaluate and manage a patient with a persistent dry cough and abdominal distension since being intubated for a procedure on [DATE]?
Which measurement obtained from a right‑heart catheterization indicates diastolic dysfunction?
What oral terbinafine dosage and duration should be used to treat tinea corporis in an adult?
In an asymptomatic patient with an incidentally discovered small pericardial effusion and normal thyroid function tests and inflammatory markers, how extensive should the diagnostic workup be?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.